Testing the efficacy and toxicity of adenylyl cyclase inhibitors against enteric pathogens using in vitro and in vivo models of infection.
Enterotoxigenic Escherichia coli (ETEC) produces the ADP-ribosyltransferase toxin known as heat-labile enterotoxin (LT). In addition to the toxic effect of LT resulting in increases of cyclic AMP (cAMP) and disturbance of cellular metabolic processes, this toxin promotes bacterial adherence to intestinal epithelial cells (A. M. Johnson, R. S. Kaushik, D. H. Francis, J. M. Fleckenstein, and P. R. Hardwidge, J. Bacteriol. 191:178-186, 2009). Therefore, we hypothesized that the identification of a compound that inhibits the activity of the toxin would have a suppressive effect on the ETEC colonization capabilities. Using in vivo and in vitro approaches, we present evidence demonstrating that a fluorenone-based compound, DC5, which inhibits the accumulation of cAMP in intoxicated cultured cells, significantly decreases the colonization abilities of adenylyl cyclase toxin-producing bacteria, such as ETEC. These findings established that DC5 is a potent inhibitor both of toxin-induced cAMP accumulation and of ETEC adherence to epithelial cells. Thus, DC5 may be a promising compound for treatment of diarrhea caused by ETEC and other adenylyl cyclase toxin-producing bacteria.
Moen
Scott T
ST
Department of Microbiology and Immunology, University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas 77555, USA.
Blumentritt
Carla A
CA
Slater
Terry M
TM
Patel
Shilpa D
SD
Tutt
Christopher B
CB
Estrella-Jimenez
Maria E
ME
Pawlik
Jennifer
J
Sower
Laurie
L
Popov
Vsevolod L
VL
Schein
Catherine H
CH
Gilbertson
Scott R
SR
Peterson
Johnny W
JW
Torres
Alfredo G
AG
D000067956:Adenylyl Cyclase Inhibitors; D018829:Adhesins, Bacterial / Q000378:metabolism*; D000818:Animals; D001422:Bacterial Adhesion / Q000187:drug effects; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors*; D002460:Cell Line; D015169:Colony Count, Microbial; D054307:Enterotoxigenic Escherichia coli / Q000472:pathogenicity*; D004768:Enterotoxins / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology / Q000633:toxicity; D004847:Epithelial Cells / Q000382:microbiology; D004927:Escherichia coli Infections / Q000517:prevention & control*; D029968:Escherichia coli Proteins / Q000037:antagonists & inhibitors*; D005260:Female; D005449:Fluorenes / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D006801:Humans; D020128:Inhibitory Concentration 50; D007421:Intestine, Small / Q000382:microbiology / Q000473:pathology; D008264:Macrophages / Q000382:microbiology; D051379:Mice
D000067956:Adenylyl Cyclase Inhibitors; D018829:Adhesins, Bacterial; D001427:Bacterial Toxins; D004768:Enterotoxins; D004791:Enzyme Inhibitors; D029968:Escherichia coli Proteins; D005449:Fluorenes; C027538:heat-labile enterotoxin, E coli